Evaluating Intermittent Theta Burst Stimulation Effects on Biomarkers and Symptoms in Treatment-Resistant Depression
Led by Gulhane Training and Research Hospital · Updated on 2026-09-14
100
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Treatment-resistant depression TRD affects many patients with major depressive disorder who do not respond well to standard antidepressant medications. This study evaluates the effects of intermittent theta burst stimulation iTBS, a non-invasive brain stimulation targeting the left dorsolateral prefrontal cortex, on clinical symptoms, executive functions, and biological markers in patients with TRD. The goal is to better understand the biological mechanisms linked to treatment response and identify potential biomarkers for improved personalized care.
Participants include 50 patients with TRD and 50 healthy controls. Patients will receive active iTBS treatment using a MagVenture X100 device, delivering 1800 pulses per session at 90% of resting motor threshold, five times per week for four weeks total 20 sessions. Healthy controls will only undergo baseline assessments without intervention. Patients will continue their usual medication during the study.
Participants will undergo clinical evaluations using depression and insomnia rating scales, and cognitive tests assessing executive function before and after treatment. Blood samples will be collected to measure inflammatory and neuroprotective biomarkers and gene expression. The primary outcome is change in depression severity after four weeks. Secondary outcomes include changes in other clinical scores, cognitive performance, biomarkers, and gene expression profiles. The study aims to support biomarker-guided personalized neuromodulation strategies for TRD.
CONDITIONS
Brief Title
Relationship of Peripheral Inflammatory and Neuroprotective Biomarkers With Response to Intermittent Theta Burst Stimulation in Treatment-Resistant Depression
Research Team
B
BEYAZIT GARİP, Principal Investigator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of Major Depressive Disorder according to DSM-5-TR criteria
Inadequate response to at least two antidepressant treatments at adequate doses and durations
Eligible for transcranial magnetic stimulation treatment
Able and willing to provide written informed consent
Able to complete neuropsychological assessments
Able to attend study visits and complete the treatment protocol
You will not qualify if you...
Schizophrenia, bipolar disorder, organic mental disorders, or other major psychiatric disorders
History of epilepsy, brain tumor, severe head trauma, or significant neurological disease
Contraindications to transcranial magnetic stimulation
Presence of intracranial metal implants, cardiac pacemakers, cochlear implants, or other incompatible implanted devices
Active infection
Autoimmune or chronic inflammatory disease
Electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation within the past 5 years
Previous intravenous or intranasal ketamine treatment
Pregnancy or breastfeeding
Active alcohol or substance use disorder
Inability to comply with study procedures or tolerate the iTBS protocol
Withdrawal of informed consent at any stage
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 4 weeks
Participants with treatment-resistant depression receive intermittent theta burst stimulation over the left dorsolateral prefrontal cortex, continuing their usual medications. Clinical assessments, cognitive testing, and blood sample collections occur before and after treatment.
5 sessions per week, total of 20 sessions
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Pilot Study on Neuroendocrine Tests Predicting Response to Repetitive Transcranial Magnetic Stimulation Treatment for Major Depression
Randomized Double-Blind Trial of ALTO-207 Versus Placebo in Adults With Treatment-Resistant Depression
Personalized Treatment Selection Using Brain Imaging and Clinical Data for Adults with Treatment-Resistant Depression Comparing rTMS and Ketamine
Evaluating Full-Spectrum Cannabidiol Oil as an Additional Treatment for Adults with Treatment-Resistant Major Depression
Study of Cognitive Decline in Older Adults with Late Life Depression using Brain Imaging and Biomarkers
Study of Light Therapy Combined With CPAP to Improve Treatment in Adults With Major Depression and Obstructive Sleep Apnea
Brain Activity and Inflammatory Biomarker Study in Adults with Treatment-Resistant Major Depression Receiving Electroconvulsive Therapy
Pilot Study of EEG-Guided Transcranial Magnetic Stimulation to Improve Treatment Outcomes in Adults With Major Depressive Disorder
Evaluating Psychobiotics with Antidepressants for Adults with Major Depressive Disorder
Study of Psilocybin Combined with Trazodone for Treatment-resistant Depression A Randomized Controlled Proof-of-Concept Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial.
Daniel M Blumberger, Fidel Vila-Rodriguez, Kevin E Thorpe...